Dipexium Pharmaceut (DPRX) Misses Q1 EPS by 4c

Dipexium Pharmaceut (NASDAQ: DPRX) reported Q1 EPS of ($0.56), $0.04 worse than the analyst estimate of ($0.52).

At March 31, 2016, the Company had cash and short-term investments totaling approximately $27.2 million, as compared to approximately $32.2 million at December 31, 2015. The Company's cash balance is currently anticipated to fund operations through 2017.

For earnings history and earnings-related data on Dipexium Pharmaceut (DPRX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49